Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Unknown 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 2 Breast Neoplasms 2 Resectable Localized Prostate Cancer 1 Recurrence 1 Radiation-induced Oral Mucositis 1 Prostate Cancer Recurrent 1 Pancreatic Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Melanoma 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 Adenocarcinoma of Lung 1

Interventions

pembrolizumab 54 Nivolumab 50 Ipilimumab 28 Cyclophosphamide 16 binimetinib 10 Specimen Handling 10 Magnetic Resonance Spectroscopy 10 fludarabine 9 Radiosurgery 9 relatlimab 8 encorafenib 8 Opdualag 8 Biopsy 8 aldesleukin 7 Interleukin-2 7 atezolizumab 6 Immunotherapy 6 Blood Specimen Collection 6 cemiplimab 5 CTLA-4 Antigen 5 Bevacizumab 5 trametinib 4 fludarabine phosphate 4 dabrafenib 4 Temozolomide 4 Paclitaxel 4 Immune Checkpoint Inhibitors 4 spartalizumab 3 Surgical Procedures, Operative 3 Metformin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Melanoma × Hydroxychloroquine × Clear all

NCT04464759 2026-05-11

LIMIT

Abramson Cancer Center at Penn Medicine

Phase 1/2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡